Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2016 Mar 25;300:13–24. doi: 10.1016/j.taap.2016.03.011

Fig. 1.

Fig. 1

AHR antagonists prevent diet-based obesity, adiposity, and hepatic steatosis. Chemical structure of (A) α-naphthoflavone (NF) and (B) CH-223191. A comparison of the effects of NF and CH-223191 on B6 male mice (n=4/experimental group) fed ad libitum at weaning control and Western diets ± NF (~3mg/kg/day) or ± CH-223191 (~10mg/kg/day) on (C) total body mass gain and (D) gonadal fat mass to total body mass ratio. (E) Food consumption for each experimental group was determined over a 5–7-day period at week 3 during the 5-wk diet regimen. (F) Total liver mass to total body mass ratio at the conclusion of the 5-wk diet regimen. (G) Representative liver sections stained with Masson’s trichrome and (H) plot of triglyceride serum levels of the same experimental groups. p-values to the corresponding vehicle-treated control group: *, ≤0.05; **, ≤0.02; ***, ≤0.002. Error bars represent standard error of the mean (SEM).